So far, immunotherapy targeting programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) has been on it way of clinical trials (13) for breast cancer, although optimal selection of ideal candidates to the immune therapy remains a challenge. The gene discussed is PDCD1; the disease is breast carcinoma.